For example, a study in Korean families found a decreased risk of CHB, RCC, and PNET in patients with VHL missense variants outside the HIF‐α binding site, compared with patients with missense VHL variants in the HIF‐α binding site and truncating variants (Liu et al., 2018). This evidence concerns the gene VHL and renal cell carcinoma.